Fabian Gerlinghaus, Cellares CEO

Up­dat­ed: Cel­lares to pro­duce Ca­balet­ta’s au­toim­mune CAR-T can­di­date 

Cel­lares an­nounced a new proof-of-con­cept part­ner­ship with Ca­balet­ta Bio to man­u­fac­ture the biotech’s au­toim­mune CAR-T cell ther­a­py.

The goal of the pro­gram is to test …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.